Go Pro
→ Oxford Club Analyst’s Urgent AI Warning (From The Oxford Club) (Ad)tc pixel Free COYA Stock Alerts

Coya Therapeutics (COYA) Competitors

Coya Therapeutics logo
$4.37 -0.18 (-3.96%)
Closing price 04:00 PM Eastern
Extended Trading
$4.36 0.00 (-0.11%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

COYA vs. OVID, CABA, BNTC, SLN, and AGMB

Should you buy Coya Therapeutics stock or one of its competitors? MarketBeat compares Coya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coya Therapeutics include Ovid Therapeutics (OVID), Cabaletta Bio (CABA), Benitec Biopharma (BNTC), Silence Therapeutics (SLN), and AgomAb Therapeutics (AGMB). These companies are all part of the "pharmaceutical products" industry.

How does Coya Therapeutics compare to Ovid Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Coya Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ovid Therapeutics has a net margin of -240.11% compared to Coya Therapeutics' net margin of -266.10%. Ovid Therapeutics' return on equity of -22.51% beat Coya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coya Therapeutics-266.10% -55.86% -48.86%
Ovid Therapeutics -240.11%-22.51%-18.67%

Ovid Therapeutics has lower revenue, but higher earnings than Coya Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coya Therapeutics$7.95M12.90-$21.23M-$1.15N/A
Ovid Therapeutics$7.25M61.27-$17.41M-$0.29N/A

In the previous week, Ovid Therapeutics had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 2 mentions for Ovid Therapeutics and 0 mentions for Coya Therapeutics. Ovid Therapeutics' average media sentiment score of 1.46 beat Coya Therapeutics' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Coya Therapeutics Neutral
Ovid Therapeutics Positive

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 250.88%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 115.34%. Given Coya Therapeutics' higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than Ovid Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

Summary

Ovid Therapeutics beats Coya Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Coya Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Coya Therapeutics has higher revenue and earnings than Cabaletta Bio. Coya Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A-$167.86M-$1.96N/A
Coya Therapeutics$7.95M12.90-$21.23M-$1.15N/A

Cabaletta Bio has a beta of 3.26, meaning that its stock price is 226% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Cabaletta Bio has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Cabaletta BioN/A -131.58% -96.46%
Coya Therapeutics -266.10%-55.86%-48.86%

Cabaletta Bio presently has a consensus target price of $15.50, suggesting a potential upside of 463.64%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 250.88%. Given Cabaletta Bio's higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than Coya Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cabaletta Bio
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Cabaletta Bio had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 2 mentions for Cabaletta Bio and 0 mentions for Coya Therapeutics. Cabaletta Bio's average media sentiment score of 0.51 beat Coya Therapeutics' score of 0.00 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company Overall Sentiment
Cabaletta Bio Positive
Coya Therapeutics Neutral

39.8% of Coya Therapeutics shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Coya Therapeutics beats Cabaletta Bio on 8 of the 15 factors compared between the two stocks.

How does Coya Therapeutics compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Benitec Biopharma currently has a consensus price target of $27.00, suggesting a potential upside of 136.01%. Coya Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 250.88%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Benitec Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Benitec Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Benitec Biopharma has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Benitec Biopharma's return on equity of -34.82% beat Coya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Benitec BiopharmaN/A -34.82% -34.11%
Coya Therapeutics -266.10%-55.86%-48.86%

In the previous week, Benitec Biopharma's average media sentiment score of 0.00 equaled Coya Therapeutics'average media sentiment score.

Company Overall Sentiment
Benitec Biopharma Neutral
Coya Therapeutics Neutral

Coya Therapeutics has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec BiopharmaN/AN/A-$37.92M-$1.14N/A
Coya Therapeutics$7.95M12.90-$21.23M-$1.15N/A

Summary

Coya Therapeutics beats Benitec Biopharma on 7 of the 12 factors compared between the two stocks.

How does Coya Therapeutics compare to Silence Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Coya Therapeutics has a net margin of -266.10% compared to Silence Therapeutics' net margin of -8,943.86%. Coya Therapeutics' return on equity of -55.86% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coya Therapeutics-266.10% -55.86% -48.86%
Silence Therapeutics -8,943.86%-105.34%-52.79%

Coya Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

In the previous week, Silence Therapeutics had 4 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Silence Therapeutics and 0 mentions for Coya Therapeutics. Silence Therapeutics' average media sentiment score of 0.45 beat Coya Therapeutics' score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Coya Therapeutics Neutral
Silence Therapeutics Neutral

Coya Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 250.88%. Silence Therapeutics has a consensus target price of $55.00, suggesting a potential upside of 364.92%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Coya Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Silence Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Coya Therapeutics has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coya Therapeutics$7.95M12.90-$21.23M-$1.15N/A
Silence Therapeutics$560K997.95-$88.61M-$1.59N/A

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Coya Therapeutics beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Coya Therapeutics compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Coya Therapeutics (NASDAQ:COYA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

39.8% of Coya Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AgomAb Therapeutics has higher earnings, but lower revenue than Coya Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgomAb TherapeuticsN/AN/AN/AN/AN/A
Coya Therapeutics$7.95M12.90-$21.23M-$1.15N/A

AgomAb Therapeutics currently has a consensus target price of $32.75, suggesting a potential upside of 182.33%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 250.88%. Given Coya Therapeutics' higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than AgomAb Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

AgomAb Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. AgomAb Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AgomAb TherapeuticsN/A N/A N/A
Coya Therapeutics -266.10%-55.86%-48.86%

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Coya Therapeutics. MarketBeat recorded 1 mentions for AgomAb Therapeutics and 0 mentions for Coya Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.00 equaled Coya Therapeutics'average media sentiment score.

Company Overall Sentiment
AgomAb Therapeutics Neutral
Coya Therapeutics Neutral

Summary

AgomAb Therapeutics and Coya Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COYA vs. The Competition

Export
MetricCoya TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$106.73M$3.68B$7.01B$12.68B
Dividend YieldN/A2.18%2.67%9.42%
P/E Ratio-3.8021.1926.8823.95
Price / Sales12.90305.97518.3593.75
Price / CashN/A155.6550.6060.45
Price / Book2.128.0010.566.16
Net Income-$21.23M$23.81M$3.60B$331.73M
7 Day Performance-9.71%-3.22%-2.15%-1.96%
1 Month Performance-17.39%-0.69%0.10%-2.49%
1 Year Performance-23.20%41.97%22.55%17.21%

Coya Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COYA
Coya Therapeutics
2.631 of 5 stars		$4.37
-4.0%		$15.33
+250.9%		-21.3%$106.73M$7.95MN/A6
OVID
Ovid Therapeutics
2.9392 of 5 stars		$2.46
+1.2%		$5.13
+108.3%		+298.1%$453.54M$7.25MN/A60
CABA
Cabaletta Bio
2.2292 of 5 stars		$2.67
-3.6%		$15.50
+480.5%		+72.0%$450.85MN/AN/A50
BNTC
Benitec Biopharma
1.6 of 5 stars		$12.98
-0.1%		$27.00
+108.0%		+6.4%$446.26MN/AN/A20
SLN
Silence Therapeutics
3.5829 of 5 stars		$9.75
+5.0%		$55.00
+464.1%		+75.9%$438.81M$560KN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 7/22/2026 by MarketBeat.com Staff.
From Our Partners
America’s answer to universal basic income
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon is about to dominate the biggest arms race in tech history
Microsoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...
The Oxford Club | Sponsoredtc pixel
Wall Street legend put 60% in one stock — here’s the ticker
One of America's most famous investors put 60% of his fund into a single stock - and Whitney Tilson of Stansbe...
Stansberry Research | Sponsoredtc pixel
It all happens tonight.
Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...
Trade Thirsty | Sponsoredtc pixel
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel